Evaluation of serum L-FABP levels in patients with acute pancreatitis

Koçak, Erdem; Akbal, Erdem; Köklü, Seyfettin; Adam, Gürhan

doi:10.5505/tjtes.2015.49879

Cited by 5 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fatty acid-binding protein was reported to be correlated with gut dysfunction and could be used for evaluating the severity of SAP in patients. 11,12 We then tested serum level of FABP in rats. As expected, FABP level of the SAP group was much higher than that of the control group (Figure 3).…”

Section: Resultsmentioning

confidence: 99%

Bidirectional Effects of Pyrrolidine Dithiocarbamate on Severe Acute Pancreatitis in a Rat Model

Yang

Guo

et al. 2019

Dose-Response

View full text Add to dashboard Cite

Introduction:The mechanism by which intestinal mucosal barrier is damaged in severe acute pancreatitis (SAP)-associated impairment is not fully understood.Methods:We established an l-arginine-induced SAP rat model, pretreated with or without pyrrolidine dithiocarbamate (PDTC). Hematoxylin and eosin staining was performed to evaluate the pathological alterations. Western blotting was conducted to detect the expression of autophagy-related proteins. Oxidative stress was assessed by the levels of malondialdehyde and superoxide dismutase.Results:We found significant injury of the intestinal mucosal barrier in SAP rats, with overexpression of Beclin-1, LC3, and p65. Pyrrolidine dithiocarbamate showed a bidirectional effect in protecting SAP rats. A high dose of PDTC aggravated disease in rats, while a low or medium dose of PDTC pretreatment, was able to alleviate tissue damage. Pyrrolidine dithiocarbamate changed the expression of Beclin-1, LC3, and p65 in the intestines. The fatty acid-binding protein level was increased in SAP rats with high-dose PDTC or without PDTC pretreatment and was reduced in SAP rats with low- or medium-dose PDTC exposure.Conclusions:Autophagy is involved in the impairment of intestinal mucosal barrier during SAP. A suitable dose of PDTC (1 or 10 mg/kg) may decrease the severity of SAP by inhibiting autophagy in intestinal mucosal cells.

show abstract

Section: Resultsmentioning

confidence: 99%

Bidirectional Effects of Pyrrolidine Dithiocarbamate on Severe Acute Pancreatitis in a Rat Model

Yang

Guo

et al. 2019

Dose-Response

View full text Add to dashboard Cite

show abstract

“…All three investigated biomarkers of intestinal injury were elevated in NOMI patients compared to controls. L-FABP, a nonspeci c biomarker of intestinal injury, which is also increased in acute pancreatitis (21) and severe traumatic abdominal injury (22), was more than tenfold increased compared to healthy control. As vasoconstriction of mesenteric arteries in NOMI also may extend to the hepatic artery (23) and L-FABP is released in response to liver ischemia (24), it is conceivable that this may indicate additional hepatic ischemia in patients with NOMI.…”

Section: Discussionmentioning

confidence: 96%

Predictors of Response To Intra-Arterial Vasodilatory Therapy of Non-Occlusive Mesenteric Ischemia In Patients With Severe Shock - Results From A Prospective Observational Study

Rittgerodt

Pape

Busch

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Non-occlusive mesenteric ischemia (NOMI) is a life-threatening condition occurring in patients with shock and is characterized by vasoconstriction of the mesenteric arteries leading to intestinal ischemia and multi-organ failure. Although minimal invasive local intra-arterial infusion of vasodilators into the mesenteric circulation has been suggested as a therapeutic option in NOMI, current knowledge is based on retrospective case series and it remains unclear which patients might benefit. Here, we prospectively analyzed predictors of response to intra-arterial therapy in patients with NOMI.Methods: Prospective single-center observational study to analyze 28-day mortality (primary outcome) and reduction of blood lactate > 2mmol/l from baseline after 24 hours (key secondary endpoint) in patients with NOMI undergoing intra-arterial vasodilatory therapy. Predictors of response to therapy concerning primary and key secondary endpoint were identified using a) clinical parameters as well as b) data from 2D-perfusion angiography and c) experimental biomarkers of intestinal injury.Results: A total of 42 patients were included into this study. At inclusion patients had severe shock, indicated by high doses of norepinephrine (NE) (median (Interquartile Range (IQR)) 0.37 (0.21-0.60) μg/kg/min), elevated lactate concentrations (9.2 (5.2-13) mmol/l), and multi-organ failure. Median intestinal fatty-acid binding protein (i-FABP) (p<0.001) and smooth muscle protein 22 (SM-22) (p<0.0001) plasma concentrations were increased compared to healthy controls indicating significant mucosal and transmural intestinal ischemia at inclusion. 28-day mortality was 71% and higher NE dose and lactate as well as lower thrombocytes, bicarbonate and pH 24 hours following intervention were associated with higher mortality. Patients showed a continuous reduction of lactate following intra-arterial prostaglandin infusion (baseline: (9.2 (5.2-13) mmol/l vs. 24 hours: 4.4 (2.5-9.1) mmol/l, p<0.001). 28-day mortality was 59% in patients with a reduction of lactate > 2 mmol/l 24 hours after inclusion (n=22), while it was 85% in all other patients (n=20) (Hazard Ratio 0.409; 95% CI, 0.14-0.631, p=0.005). Conclusions: A reduction of lactate concentrations was observed following implementation of intra-arterial therapy and lactate reduction was associated with better survival. Our findings concerning outcome predictors in NOMI patients undergoing intra-arterial prostaglandin therapy might help designing a randomized controlled trial to further investigate this therapeutic approach. Trial registration: Retrospectively registered January 22th 2020 at clinicaltrials.gov (REPERFUSE, NCT04235634), https://clinicaltrials.gov/ct2/show/NCT04235634?cond=NOMI&draw=2&rank=1

show abstract

“…ET is produced by enteric pathogens, and can also enter the circulating blood in large quantities when the intestinal mucosal function is impaired and cause toxaemia [26]. Also, when intestinal ischemia damage occurs, the permeability of intestinal epithelial cells increases and FABP enters the blood circulation through the capillaries and is detected in the peripheral blood [27]. Besides, AMY is an effective indicator for the early diagnosis of AP [28].…”

Section: Adverse Reactionsmentioning

confidence: 99%

The Effect of Somatostatin Combined With Omeprazole on Patients With Severe Acute Pancreatitis

Hong¹

2021

FARMACIA

View full text Add to dashboard Cite

This study aimed to investigate the effects of somatostatin (SST) combined with omeprazole (OMZ) on patients with severe acute pancreatitis (SAP). Ninety-eight SAP patients were randomly divided into two groups (control group and experimental group). The control group received conventional SAP treatment, and the experimental group received conventional and SST-OMZ treatment for two weeks. The differences in serum levels of various indicators and biomarkers between the two groups on admission and after two weeks of treatment were compared. The results showed that after two weeks of treatment, in the experimental group the systemic inflammation and oxidative stress were inhibited, protecting the intestinal mucosal barrier function and regulating the gastrointestinal hormones and improve the therapeutic effect of standard SAP treatment with a decrease in the occurrence of adverse reactions. RezumatStudiul a avut ca scop investigarea efectelor asocierii somatostatinei (SST) cu omeprazolul (OMZ) la pacienți cu pancreatită acută severă (SAP). Nouăzeci și opt de pacienți cu SAP au fost împărțiți în două grupuri (grupul control și grupul experimental). Grupul control a primit tratament SAP convențional, iar grupul experimental a primit tratament convențional și SST-OMZ timp de două săptămâni. Au fost comparate nivelurile serice ale diferiților indicatori și biomarkeri între cele două grupuri, la internare și după două săptămâni de tratament. Rezultatele au arătat că după două săptămâni de tratament, în grupul experimental, inflamația sistemică și stresul oxidativ au fost inhibate. Efectul protector asupra funcției de barieră a mucoasei intestinale a fost semnificativ, nivelul hormonilor gastrointestinali a fost îmbunătățit, iar tratamentul standard SAP a înregistrat o scădere a incidenței reacțiilor adverse.

show abstract

Evaluation of serum L-FABP levels in patients with acute pancreatitis

Abstract: BACKGROUND:The aim of this study was to assess the serum L-FABP levels in patients with acute pancreatitis and compare with healthy subjects.

Cited by 5 publications

References 17 publications

Bidirectional Effects of Pyrrolidine Dithiocarbamate on Severe Acute Pancreatitis in a Rat Model

Bidirectional Effects of Pyrrolidine Dithiocarbamate on Severe Acute Pancreatitis in a Rat Model

Predictors of Response To Intra-Arterial Vasodilatory Therapy of Non-Occlusive Mesenteric Ischemia In Patients With Severe Shock - Results From A Prospective Observational Study

The Effect of Somatostatin Combined With Omeprazole on Patients With Severe Acute Pancreatitis

Contact Info

Product

Resources

About